GEMALTO
3.4.2018 07:02:11 CEST | Business Wire | Press release
Gemalto (Euronext NL0000400653 GTO), the world leader in digital security, today announced that SafeNet KeySecure has been validated for use with the latest release of NetApp® Volume Encryption (NVE) data management solution. As a result, NetApp customers do not need to encrypt the entire disk drive; they can choose to encrypt granularly at the volume level without the need and additional cost of purchasing self encrypting drives (SEDs), while retaining key benefits such as centralized key management and access control, better compliance, and high availability.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180402005033/en/
Data privacy and data security continues to be a key focus for organizations, especially in light of industry compliance standards such as US health standard (HIPAA) or payment card standard (PCI-DSS) and the EU’s General Data Protection Regulation (GDPR ). SafeNet KeySecure centralizes cryptographic processing, security policy and key management, while offering NetApp customers the ability to store and manage encryption keys centrally and separately, away from the encrypted data ensuring security and facilitating compliance.
“Data has become one of the most valuable assets for organizations, but as with anything with value, criminals are determined to get their hands on it,” said Todd Moore, Gemalto Senior Vice President for Encryption Products. “With legislation forcing companies to reveal breaches such as the GDPR, which is due to come into effect in May, there will be nowhere for organizations to hide. This increase in attention means that they must find a way to control who has access to their data and ensure they’re putting in the necessary tools to protect it.”
The Gemalto SafeNet KeySecure solution builds on the NetApp Data Fabric software approach, which simplifies and integrates data management across the cloud and on premises to accelerate digital transformation. On top of having more granular data encryption and keeping keys separate, customers will have the freedom to choose any storage media, have flexible deployment options, audit trails, separation of duties and ecosystem support.
“The NetApp Alliance Partner Program enables us to join forces with the best and brightest in the industry, to address the storage and data infrastructure needs of today’s complex enterprise environments,” said Deepak Visweswaraiah, Senior Vice President, Manageability Products and Solutions Group, at NetApp. “As a result of working with the world leader in digital security, we can now offer our customers peace-of-mind that their data is safe and compliant.”
For more information on Gemalto SafeNet KeySecure:
- Read this blog: Benefits of External Key Management for Storage
- Download the SafeNet KeySecure and SafeNet Virtual KeySecure product briefs
About Gemalto
Gemalto (Euronext NL0000400653 GTO) is the global leader in digital security , with 2017 annual revenues of €3 billion and customers in over 180 countries. We bring trust to an increasingly connected world.
From secure software to biometrics and encryption, our technologies and services enable businesses and governments to authenticate identities and protect data so they stay safe and enable services in personal devices, connected objects, the cloud and in between.
Gemalto’s solutions are at the heart of modern life, from payment to enterprise security and the internet of things. We authenticate people, transactions and objects, encrypt data and create value for software – enabling our clients to deliver secure digital services for billions of individuals and things.
Our 15,000 employees operate out of 114 offices, 40 personalization and data centers, and 35 research and software development centers located in 47 countries.
For more information visit www.gemalto.com , or follow @gemalto on Twitter.
NETAPP, the NETAPP logo, and the marks listed at http://www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180402005033/en/
Contact:
Gemalto media contacts:
Tauri Cox
North America
+1
512 257 3916
tauri.cox@gemalto.com
or
Sophie
Dombres
Europe Middle East & Africa
+33 4 42 55 36 57 38
sophie.dombres@gemalto.com
or
Jaslin
Huang
Asia Pacific
+65 6317 3005
jaslin.huang@gemalto.com
or
Enriqueta
Sedano
Latin America
+52 5521221422
enriqueta.sedano@gemalto.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom